Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View OFIX insider activity ↗

OFIXOrthofix Medical Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$92.19M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$822.31MYear ended December 31, 2025
Profit or loss-$92.19MYear ended December 31, 2025
Cash from the business$33.35MYear ended December 31, 2025
Total assets$873.02MAs of June 30, 2026
Total liabilities$443.84MAs of June 30, 2026
Cash & equivalents$103.81MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$453.04M
2018-12
$459.96M
2019-12
$406.56M
2020-12
$464.48M
2021-12
$460.71M
2022-12
$746.64M
2023-12
$799.49M
2024-12
$822.31M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$822,312,000February 24, 202610-K ↗
January 1, 2024 – December 31, 2024$799,491,000February 24, 202610-K ↗
January 1, 2023 – December 31, 2023$746,641,000February 24, 202610-K ↗
January 1, 2022 – December 31, 2022$460,713,000February 25, 202510-K ↗
January 1, 2021 – December 31, 2021$464,479,000March 5, 202410-K ↗
January 1, 2020 – December 31, 2020$406,562,000March 6, 202310-K ↗
January 1, 2019 – December 31, 2019$459,955,000February 25, 202210-K ↗
January 1, 2018 – December 31, 2018$453,042,000February 26, 202110-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 12, 2026

Response SHA-256: da61b734ddb5cf160086a3c093d51eb06d7c3373b242de97d4adc92c07613c40

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.